Multi-Omics Wellness Packages
What multi-omics wellness packages bundle, what research profiling studies actually showed, how they are regulated in the US, and why outcome evidence for healthy buyers was not found.
Content last updated . This page has not been medically reviewed.
What the packages claim
A multi-omics wellness package combines several kinds of molecular tests, for example DNA, gene activity (transcriptomics), proteins (proteomics), metabolites (metabolomics) and the microbiome, and sells a "complete picture" of health, often with a personalized plan. This page checks the claims. It is information only and not medical advice, and it does not rank or name products. The field itself is explained in multi-omics explained, and the test panels are covered in multi-omics test panels.What research profiling studies did
Research studies of deep personal profiling exist, and they are the source of much of the marketing language.| Study | Who and what | What it showed |
|---|---|---|
| Chen and colleagues, 2012 | One person, genomic, transcriptomic, proteomic, metabolomic and autoantibody profiles over 14 months [1] | The profile revealed medical risks, including type 2 diabetes, and showed that molecular activity changes over time [1] |
| Price and colleagues, 2017 | 108 individuals followed for 9 months with genomes, clinical tests, metabolomes, proteomes, microbiomes and activity tracking [2] | Correlation networks and candidate biomarkers; behavioral coaching informed by the data helped participants improve clinical biomarkers [2] |
| Ahadi and colleagues, 2020 | 106 healthy people aged 29 to 75, deep longitudinal multiomics [3] | Markers associated with age and proposed "ageotypes" [3] |
These are research studies, not tests of whether a commercial package improves health. The outcomes were correlations, candidate biomarkers and biomarker change. A biomarker change is not a clinical outcome, as explained in biomarkers vs clinical outcomes. The 2012 study followed a single person, so it cannot show how often such profiling helps anyone. [1]
Evidence for benefit in healthy buyers
Proper evidence not found. For this page, PubMed was searched on 2026-10-22 for randomized trials of multi-omics profiling in healthy adults with health outcomes, and the results were mostly studies measuring molecular changes after a diet, fasting or other intervention rather than testing whether buying a profile improves health. A narrative review of predictive biomarkers in asymptomatic adults reached a related conclusion: many widely marketed biomarkers lack evidence of clinical utility, offer limited actionable benefits, or perform poorly in primary care populations. [4] It also reported that only a minority meet the thresholds of analytical validity, clinical validity and clinical utility required for preventive use. [4] This is a review of biomarkers in general, not of one product.Claim analysis
| Claim | What to check |
|---|---|
| "Complete picture of your health" | Each layer has its own error rates and reference ranges. Review articles describe false positives as a documented unintended consequence of marketed biomarkers. [4] See false positives, multiple testing and incidental findings. |
| "Personalized plan" | Was the plan tested against standard advice in a trial with health outcomes? See claim check: personalized means better. |
| "Detects problems early" | Early detection needs proof that acting early helps. Overdiagnosis and diagnostic cascades are documented unintended consequences of biomarker testing. [4] |
| "Biological age" | Clock scores are not clinical outcomes. See biomarkers and biological age tests. |
| "Backed by research" | Research on the field is not research on the product. |
Genetic and privacy parts of a package
The DNA part inherits the issues in genetic test false positives and clinical confirmation, variant interpretation and uncertain significance and ancestry and population applicability. Your data also raises the questions in genetic privacy and incidental findings.Frequently asked questions
Does a multi-omics test prove how healthy I am?
No. Research profiling studies found correlations and candidate biomarkers in small groups. [2] They did not show that buying a package improves health.
Are the studies behind these packages about the packages?
No. They are research studies of 1 to 108 people, run by research teams. [1][2]
Does the FDA approve multi-omics packages?
The FDA page reviewed does not name multi-omics packages. It says it generally does not review laboratory developed tests offered only on a provider's prescription. [5]
Should I use a package to choose supplements or diets?
This site cannot recommend that. Evidence of benefit from doing so was not found. Talk with a clinician or registered dietitian.
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
How to read the evidence labels
Labels used on this page: promising but limited (research profiling), insufficient evidence (benefit for healthy buyers) and marketing claim. The full set is explained in how we label evidence.
Regulation (US)
In the US, the FDA describes direct-to-consumer tests as in vitro diagnostics marketed without a health care provider's involvement. [5] For tests of this kind it reviews analytical validity, clinical validity and the claims the company makes. [5] It generally does not review laboratory developed tests created and performed in a single laboratory and offered only when a provider prescribes them, and such tests typically lack the FDA's independent assurance of validity. [5] The FDA's May 2024 rule on laboratory developed tests was vacated by a federal court on March 31, 2025. [6] The FDA page reviewed does not mention multi-omics packages as a category, so the status of a particular package must be checked with the company and the regulator. This is US only, laws change, and it is not legal advice. A clearance for one test does not validate another test or a marketing claim.
Safety note
Do not start or stop any medicine, supplement or diet because of a package result, and do not treat a report as a diagnosis. If a result worries you, ask a clinician which parts need confirmation.
References
- Chen R, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012. PMID 22424236. Read 2026-10-22.
- Price ND, et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat Biotechnol. 2017. PMID 28714965. Read 2026-10-22.
- Ahadi S, et al. Personal aging markers and ageotypes revealed by deep longitudinal profiling. Nat Med. 2020. PMID 31932806. Read 2026-10-22.
- Wiedermann CJ, et al. Predictive biomarkers for asymptomatic adults: opportunities, risks, and guidance for general practice. Diagnostics (Basel). 2026. PMID 41594172. Read 2026-10-22.
- U.S. Food and Drug Administration. Direct-to-Consumer Tests. Read 2026-10-22.
- U.S. Food and Drug Administration. Laboratory Developed Tests. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.